Paul Saunders: And one more for me, if you don’t mind. Just a question on the inventory. I know it sounds like this delivery got pushed back because of it sounds like packaging issues. So I know it’s sort of inflated due to that. But just kind of running the rough math, if that were fully finished. It looks like it’s like 1.5 million courses of inventory. I’m just kind of curious, that’s obviously a lot more than what you’re going to deliver in the next quarter or two. So just kind of can you provide any color on that inventory build in excess of what you’re going to deliver this upcoming quarter?
Phillip Louis Gomez: Yes, so for those that may not know, the cycle time for making our product is certainly given normal scheduling and proactive scheduling of batches and manufacturing. We have four different manufacturers. It takes well over a year to go through the cycle time of our product. With BARDA, we have pretty good visibility into how that replenishment is going to go. And historically, we had a long lead time but we are now at a more mature place in our business where we want to make sure that we’re able to have a responsive supply chain that doesn’t start from zero, but may have targeted active pharmaceutical ingredient in inventory. And so if we have an opportunity for a sale, we’ll able to translate that into product in months as opposed to over a year.
So you will see in general, an increase on our balance sheet of inventory that we manage to make sure if we have an opportunity to accelerate orders with a customer, we can do that, if we ever had a disruption in our supply chain, we’ll be ready to do that. And we have a lot of flexibility given the stability of our API. And as you point out, we do have a bolus that’s getting ready for a large delivery to BARDA. We also anticipate next year, as we’ve said many times, an expiry schedule that will have another $113 million option that would be exercised, and another IV option. So we’re also building inventory to make sure we’re ready for those orders, not just the next quarter.
Paul Saunders: Yes, that makes a lot of sense. I appreciate that. And if you don’t mind, just with the — I assume it was the packaging, why that option exercise didn’t get to live this quarter. Was that — like can you also provide any more color on what happened there with the packaging? And I guess maybe how to sort of avoid that in the future.
Phillip Louis Gomez: Yes, it’s a great question, Paul. We work with a lot of service providers. And as we said, we haven’t run into any problems per se, but it’s just taken longer to get into those facilities, get it packaged and get it out. We certainly plan in advance for that, but then we have a sprint once we get the order and have to do the packaging. Historically, that’s actually been an area that’s gone very smoothly and rapidly. It just turns out this year, we run into delays there, not any technical challenges simply delays. And I can assure everyone our team has been working really hard to find ways to make sure we hit the target, but we wanted to highlight that as the challenge that we’re focused on right now.
Paul Saunders: Sounds good. Thanks Phil.
Phillip Louis Gomez: Thanks, Paul.
Operator: Thank you. There are no further questions at this time. Please proceed.
Phillip Louis Gomez: I’d like to thank everybody for their time today. We really appreciate the update and look forward to talking to you again soon. Thank you, operator. Have a good day, everybody.
Operator: Thank you. Ladies and gentlemen, that does conclude our conference for today. Thank you all for participating. You may all disconnect.
